13F Holdings
中文EN

PHAR Pharming Group N.V. IFRS Annual reports only

Pharmaceutical Preparations · Nasdaq · SEC CIK 1828316 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY26.6%
TTM net income YoY124.1%
TTM EPS YoY122.2%
Revenue 3-yr CAGR22.3%
Net income 3-yr CAGR-40.7%

Margins

Gross margin87.9%
Operating margin6.9%
Net margin0.8%
FCF margin14.3%
EBITDA margin—

Returns

ROE1.1%
ROA0.6%
ROIC (approx.)8.7%
Asset turnover0.84x

Leverage & solvency

Liabilities / assets44.6%
Debt / equity0.00x
Current ratio2.59x
Interest coverage131.85x

Cash quality & payout

Operating cash flow / net income19.19x
Accruals ratio-11.5%
Payout ratio—
Capex / revenue0.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY2022*2022-12-31FY2021*2021-12-31
Income statement
Revenue$376.13M$297.20M$245.32M$205.62M$198.87M
Cost of revenue$45.50M$35.40M$25.21M$17.56M$21.14M
Gross profit$330.63M$261.80M$220.10M$188.06M$177.73M
R&D expense$100.37M$83.15M$68.91M$52.53M$70.37M
SG&A expense$79.96M$70.65M$55.88M$46.02M$36.97M
Operating income$25.84M-$8.62M-$5.39M$18.23M$13.56M
Interest expense$196,000$56,000$134,000$105,000$94,000
Pretax income$12.85M-$8.49M-$12.01M$14.99M$23.08M
Income tax$10.31M$3.35M-$1.46M$1.31M$7.08M
Net income$2.85M-$11.84M-$10.55M$13.67M$16.00M
EBITDA————$19.95M
EPS (basic)0.00-0.02-0.020.020.03
EPS (diluted)0.00-0.02-0.020.020.02
Weighted avg. shares (diluted)746.87M785.41M725.46M707.14M701.15M
Balance sheet
Cash & equivalents$145.31M$54.94M$61.74M$207.34M$191.92M
Receivables$54.70M$54.82M$46.16M$27.62M$29.98M
Inventory$64.90M$55.72M$56.76M$42.33M$27.31M
Current assets$299.47M$278.44M$316.34M$277.50M$249.44M
PP&E, netmay include right-of-use assets (IFRS)$7.23M$7.75M$9.69M$10.39M$13.22M
Intangibles$135.54M$61.04M$71.27M$75.12M$83.83M
Total assets$499.96M$399.99M$462.85M$425.80M$397.31M
Current liabilities$115.79M$73.80M$77.97M$59.70M$46.77M
Total liabilities$222.86M$178.92M$244.07M$221.16M$204.40M
Shareholders' equity$277.10M$221.06M$218.78M$204.64M$192.92M
Shares outstanding701.68M680.31M671.07M656.35M648.75M
Cash flow statement
Operating cash flow$54.71M-$1.79M-$17.30M$22.46M$37.84M
Capital expenditure$749,000$790,000$1.44M$1.38M$10.74M
Free cash flow$53.96M-$2.58M-$18.74M$21.08M$27.10M
Investing cash flow$26.25M$31.62M-$129.39M$5.32M-$21.30M
Financing cash flow$1.50M-$34.41M-$1.04M-$4.98M-$27.95M
Depreciation & amortization————$6.39M
Stock-based compensation$13.77M$11.25M$9.25M$6.39M$9.06M

Free plan shows the latest 5 periods; Pro shows all 8 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.